Literature DB >> 21132295

Correlation between tumor budding and post-resection prognosis in patients with invasive squamous cell carcinoma of the thoracic esophagus.

Yoshitsugu Nakanishi1, Masanori Ohara, Hiromitsu Doumen, Noriko Kimura, Takuzo Ishidate, Satoshi Kondo.   

Abstract

BACKGROUND: Tumor budding is defined as an isolated single cancer cell or a cluster of cancer cells composed of fewer than five cells at the invasive front of a tumor. The aim of the present study was to identify correlations between tumor budding and clinicopathological factors and their impact on postoperative prognosis in invasive squamous cell carcinoma of the thoracic esophagus.
METHODS: The subjects were 82 patients who underwent curative resection. The number of tumors showing budding was counted immunohistochemically based on positivity for cytokeratin (AE1/AE3) to distinguish cancer cells from inflammatory cells, and the patients were divided into low-grade and high-grade budding groups. High-grade budding was defined as ≥5 budding foci per field under a 20× objective lens.
RESULTS: One group of 36 patients (43.9%) and a second group of 46 patients (56.1%) were classified into the low-grade and high-grade budding groups, respectively. Patients in the high-grade budding group had significantly larger tumor size, deeper depth of invasion, more frequent lymphatic invasion and venous invasion, as well as more lymph node metastases, than those in the low-grade budding group. Disease-free and overall survivals were worse in the high-grade budding group than in the low-grade budding group (P<0.0001 and P=0.0002, respectively). Three of four patients who had tumor recurrence more than 5 years postoperatively belonged to the low-grade budding group.
CONCLUSIONS: Tumor budding appears to be an indicator of tumor growth and invasiveness. Patients with low-grade budding are likely to have a better prognosis than those with high-grade budding, but the tumor may recur in the late phase postoperatively in patients with low-grade budding.

Entities:  

Mesh:

Year:  2011        PMID: 21132295     DOI: 10.1007/s00268-010-0880-y

Source DB:  PubMed          Journal:  World J Surg        ISSN: 0364-2313            Impact factor:   3.352


  20 in total

1.  Risk factors for an adverse outcome in early invasive colorectal carcinoma.

Authors:  Hideki Ueno; Hidetaka Mochizuki; Yojiro Hashiguchi; Hideyuki Shimazaki; Shinsuke Aida; Kazuo Hase; Susumu Matsukuma; Tadao Kanai; Hiroyuki Kurihara; Kotaro Ozawa; Kazuyoshi Yoshimura; Shinya Bekku
Journal:  Gastroenterology       Date:  2004-08       Impact factor: 22.682

2.  Intensity of tumor budding and its prognostic implications in invasive colon carcinoma.

Authors:  Ki-Jae Park; Hong-Jo Choi; Mee-Sook Roh; Hyuk-Chan Kwon; Choongrak Kim
Journal:  Dis Colon Rectum       Date:  2005-08       Impact factor: 4.585

3.  Tumour 'budding' as an index to estimate the potential of aggressiveness in rectal cancer.

Authors:  H Ueno; J Murphy; J R Jass; H Mochizuki; I C Talbot
Journal:  Histopathology       Date:  2002-02       Impact factor: 5.087

4.  A new prognostic staging system for rectal cancer.

Authors:  Hideki Ueno; Ashley B Price; Kay H Wilkinson; Jeremy R Jass; Hidetaka Mochizuki; Ian C Talbot
Journal:  Ann Surg       Date:  2004-11       Impact factor: 12.969

5.  CD8+ lymphocytes/ tumour-budding index: an independent prognostic factor representing a 'pro-/anti-tumour' approach to tumour host interaction in colorectal cancer.

Authors:  A Lugli; E Karamitopoulou; I Panayiotides; P Karakitsos; G Rallis; G Peros; G Iezzi; G Spagnoli; M Bihl; L Terracciano; I Zlobec
Journal:  Br J Cancer       Date:  2009-09-15       Impact factor: 7.640

6.  Budding as a useful prognostic marker in pT3 well- or moderately-differentiated rectal adenocarcinoma.

Authors:  Takashi Okuyama; Masatoshi Oya; Hiroshi Ishikawa
Journal:  J Surg Oncol       Date:  2003-05       Impact factor: 3.454

7.  Prognostic value of tumor "budding" in patients with colorectal cancer.

Authors:  K Hase; C Shatney; D Johnson; M Trollope; M Vierra
Journal:  Dis Colon Rectum       Date:  1993-07       Impact factor: 4.585

8.  Multivariate analysis of the pathologic features of esophageal squamous cell cancer: tumor budding is a significant independent prognostic factor.

Authors:  Masahiko Koike; Yasuhiro Kodera; Yuichi Itoh; Goro Nakayama; Michitaka Fujiwara; Nobuyuki Hamajima; Akimasa Nakao
Journal:  Ann Surg Oncol       Date:  2008-04-12       Impact factor: 5.344

Review 9.  Epithelial-mesenchymal transition mediated tumourigenesis in the gastrointestinal tract.

Authors:  Ammar Natalwala; Robert Spychal; Chris Tselepis
Journal:  World J Gastroenterol       Date:  2008-06-28       Impact factor: 5.742

10.  Tumour budding at the deepest invasive margin correlates with lymph node metastasis in submucosal colorectal cancer detected by anticytokeratin antibody CAM5.2.

Authors:  S Kazama; T Watanabe; Y Ajioka; T Kanazawa; H Nagawa
Journal:  Br J Cancer       Date:  2006-01-30       Impact factor: 7.640

View more
  10 in total

1.  C4.4A is associated with tumor budding and epithelial-mesenchymal transition of colorectal cancer.

Authors:  Ryota Oshiro; Hirofumi Yamamoto; Hidekazu Takahashi; Masahisa Ohtsuka; Xin Wu; Junichi Nishimura; Ichiro Takemasa; Tsunekazu Mizushima; Masataka Ikeda; Mitsugu Sekimoto; Nariaki Matsuura; Yuichiro Doki; Masaki Mori
Journal:  Cancer Sci       Date:  2012-04-11       Impact factor: 6.716

Review 2.  Tumour budding in solid cancers.

Authors:  Alessandro Lugli; Inti Zlobec; Martin D Berger; Richard Kirsch; Iris D Nagtegaal
Journal:  Nat Rev Clin Oncol       Date:  2020-09-08       Impact factor: 66.675

Review 3.  Tumor Budding: The Name is EMT. Partial EMT.

Authors:  Alexandru Dan Grigore; Mohit Kumar Jolly; Dongya Jia; Mary C Farach-Carson; Herbert Levine
Journal:  J Clin Med       Date:  2016-04-29       Impact factor: 4.241

4.  Decreased miR-320a promotes invasion and metastasis of tumor budding cells in tongue squamous cell carcinoma.

Authors:  Nan Xie; Cheng Wang; Zehang Zhuang; Jinson Hou; Xiqiang Liu; Yue Wu; Haichao Liu; Hongzhang Huang
Journal:  Oncotarget       Date:  2016-10-04

5.  Introducing a novel highly prognostic grading scheme based on tumour budding and cell nest size for squamous cell carcinoma of the uterine cervix.

Authors:  Moritz Jesinghaus; Johanna Strehl; Melanie Boxberg; Frido Brühl; Adrian Wenzel; Björn Konukiewitz; Anna M Schlitter; Katja Steiger; Arne Warth; Andreas Schnelzer; Marion Kiechle; Matthias W Beckmann; Aurelia Noske; Arndt Hartmann; Grit Mehlhorn; Martin C Koch; Wilko Weichert
Journal:  J Pathol Clin Res       Date:  2018-03-08

Review 6.  Tumour budding and its clinical implications in gastrointestinal cancers.

Authors:  Inti Zlobec; Martin D Berger; Alessandro Lugli
Journal:  Br J Cancer       Date:  2020-06-30       Impact factor: 7.640

7.  CD44v9 is associated with epithelial-mesenchymal transition and poor outcomes in esophageal squamous cell carcinoma.

Authors:  Daisuke Taniguchi; Hiroshi Saeki; Yuichiro Nakashima; Kensuke Kudou; Ryota Nakanishi; Nobuhide Kubo; Koji Ando; Eiji Oki; Yoshinao Oda; Yoshihiko Maehara
Journal:  Cancer Med       Date:  2018-11-26       Impact factor: 4.452

8.  Tumor budding is a significant indicator of a poor prognosis in lung squamous cell carcinoma patients.

Authors:  Ryota Masuda; Hiroshi Kijima; Naoko Imamura; Naohiro Aruga; Yusuke Nakamura; Daisuke Masuda; Haruka Takeichi; Nobusuke Kato; Tomoki Nakagawa; Makiko Tanaka; Sadaki Inokuchi; Masayuki Iwazaki
Journal:  Mol Med Rep       Date:  2012-08-27       Impact factor: 2.952

Review 9.  Tumor budding in upper gastrointestinal carcinomas.

Authors:  Viktor H Koelzer; Rupert Langer; Inti Zlobec; Alessandro Lugli
Journal:  Front Oncol       Date:  2014-08-14       Impact factor: 6.244

10.  Invasion Types Are Associated With Poor Prognosis in Lung Squamous Carcinoma Patients.

Authors:  Yang Zhao; Hongchang Shen; Chen Qiu; Tiehong Zhang; Pingping Hu; Xiao Qu; Qi Liu; Jiajun Du
Journal:  Medicine (Baltimore)       Date:  2015-10       Impact factor: 1.817

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.